Telix at SUO 2025
Join Telix at the 2025 Society of Urologic Oncology (SUO) Annual Meeting, one of the world’s leading international congresses dedicated to advances in urologic cancer care. Telix will be showcasing its Phase 3 precision imaging and therapeutic trials in prostate and kidney cancer.
Explore our presence at SUO 2025 and learn more about how Telix is advancing innovation across urologic oncology.
December 2 – 5, 2025
Sheraton Phoenix Downtown Phoenix, Arizona
Telix Pharmaceuticals
ProstACT Global: Phase 3 study of Lutetium (Lu177) rosopatamab tetraxetan plus SoC vs SoC alone in patients with metastatic castration-resistant prostate cancer
Yale School of Medicine
BiPASS: Phase 3 study of ⁶⁸Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer
UCLA Health
ZIRCON-X: Impact of ⁸⁹Zr-girentuximab PET/CT versus conventional imaging on clinical decision-making in patients with indeterminate renal masses